Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis
This study has been completed.
Sponsor:
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Collaborators:
Gilead Sciences
Merck
Information provided by (Responsible Party):
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
ClinicalTrials.gov Identifier:
NCT00822315
First received: January 13, 2009
Last updated: January 17, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Raltegravir is a potent antiretroviral agent that could be used as an alternative to efavirenz in HIV-1 infected patients with tuberculosis. However due to pharmacokinetic interactions, the optimal dose of raltegravir to be used in combination with rifampin is currently unknown.
This phase II open-label randomized multicenter trial is designed to estimate the antiviral efficacy of two doses of raltegravir and one dose of efavirenz at week 24, in HIV-1 naive patients co-infected with active tuberculosis (TB) treated with rifampin.
Condition | Intervention | Phase |
---|---|---|
HIV Infections Tuberculosis |
Drug: efavirenz Drug: raltegravir |
Phase 2 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | Phase II Open-label Randomized Multicenter Trial to Compare the Efficacy and Safety of Two Different Doses of Raltegravir and Efavirenz, All in Combination With Tenofovir and Lamivudine, in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis |
Resource links provided by NLM:
Genetics Home Reference related topics:
complement factor I deficiency
Drug Information available for:
Rifampin
Lamivudine
Tenofovir
Efavirenz
Raltegravir
Raltegravir potassium
U.S. FDA Resources
Further study details as provided by French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS):
Primary Outcome Measures:
- Virologic success, using Time to Loss of Virologic Response (TLOVR) algorithm: -Plasma HIV RNA below 50 copies/ml at week 20, confirmed at week 24 -Absence of permanent treatment discontinuation -Absence of death -Still follow-up at week 24 [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Proportion of patients with virologic response with the following definitions: - Plasma HIV RNA <50 copies/ml at week 24 - Rate of strategy discontinuation and treatment changes - Proportion of death - Proportion of patients loss to follow-up [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
- Proportion of patients with virologic response with the following definitions: o Plasma HIV RNA <50 copies/ml o Plasma HIV RNA <400 copies/ml [ Time Frame: 24 and 48 weeks ] [ Designated as safety issue: No ]
- Evolution in HIV RNA and HIV DNA (total and 2 LTR circular) from baseline to week 48 [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
- Rate of viral resistance mutations in the plasma at the time of virologic failure and in comparison with HIV-RNA mutations at W0 [ Time Frame: At the time of virologic failure ] [ Designated as safety issue: No ]
- Evolution of CD4 cell counts from baseline to week 48 [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
- Frequency, type and time to a new AIDS-defining event or death [ Time Frame: Through out the trial ] [ Designated as safety issue: Yes ]
- Frequency, type, time to grade 3 or 4 adverse event [ Time Frame: Through out the trial ] [ Designated as safety issue: Yes ]
- Rate of success of TB treatment [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
- Anti-TB resistance rate [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
- Evolution of raltegravir and efavirenz trough concentration [ Time Frame: Through out the trial ] [ Designated as safety issue: No ]
Enrollment: | 155 |
Study Start Date: | July 2009 |
Study Completion Date: | June 2012 |
Primary Completion Date: | November 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Active Comparator: 1
efavirenz
|
Drug: efavirenz
tenofovir 245 mg / lamivudine 300 mg / efavirenz 600 mg
|
Experimental: 2
raltegravir 400 mg
|
Drug: raltegravir
tenofovir 245 mg / lamivudine 300 mg / raltegravir 400 mg
|
Experimental: 3
raltegravir 800 mg
|
Drug: raltegravir
tenofovir 245 mg / lamivudine 300 mg / raltegravir 800 mg
|
Eligibility
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Adult patients (at least 18 years old)
- Plasma HIV RNA > 1000 copies/ml
- HIV-1-infection confirmed by ELISA and Western blot or Immunofluorescence
- ART naïve patients or
- ART for less than 3 months and more than 6 months ago ; an HIV resistance genotype at baseline showing no mutation to NNRTI and TDF or 3TC will be required
- For women of childbearing age, negative urinary test for pregnancy and to accept contraceptive methods: condom use and intra-uterine device when possible or declare no wish of pregnancy in the coming year.
- Confirmed or probable TB
- TB treatment including rifampin started since 2 to 8 weeks before randomisation
- Signed informed consent form
- For French patients, to be affiliated to the National Health Care System
Exclusion Criteria:
- HIV-2 infection (single or with HIV-1)
- Woman who is pregnant or likely to become so, is breastfeeding or refuses to use contraception
- ALT>2.5N, Hb <7g/dl, neutrophils < 750/mm3, platelet<50 000/mm3, bilirubin >5N, lipase >3N
- Creatinine clearance <60ml/min as assessed by the Cockcroft method
- Ongoing psychiatric pathology or any condition (including, but not limited to, the consumption of alcohol or drugs) which might, in the investigator's opinion, compromise the safety of treatment and/or patient compliance with the protocol
- Concomitant treatments including phenytoin or phenobarbital (compounds interacting with UGT1A1)
- Prior TB with a Mycobacterium tuberculosis strain resistant to rifampin
- TB treatment started for more than 8 weeks before randomisation
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00822315
Locations
Brazil | |
Hospital Genral de Nova Iguaçu | |
Nova Iguaçu, Brazil | |
Hospital Sanatorio Pertenon | |
Porto Alegre, Brazil | |
Hospital Nossa Senhora da Coceiçao | |
Porto alegre, Brazil | |
Ipec/Fiocruz | |
Rio de Janeiro, Brazil | |
Hospitral Universitario Pr Edgar Santos | |
Salvador da Bahia, Brazil | |
STD/AIDS department | |
Sao Paulo, Brazil | |
France | |
Hôpital Lariboisière | |
Paris, France, 75010 | |
Hôpital Saint-Louis | |
Paris, France, 75010 | |
CHI Villeneuve Saint Georges | |
Villeneuve Saint Georges, France, 94195 |
Sponsors and Collaborators
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Gilead Sciences
Merck
Investigators
Study Chair: | Beatriz Grinsztejn, MD | Fiocruz, Rio de Janiero, Brazil |
Study Chair: | Jean-Michel Molina, MD | Hôpital Saint-Louis, Paris, France |
More Information
No publications provided
Keywords provided by French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS):
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 03, 2013
No publications provided
Responsible Party: | French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) |
ClinicalTrials.gov Identifier: | NCT00822315 History of Changes |
Other Study ID Numbers: | ANRS 12180 REFLATE TB |
Study First Received: | January 13, 2009 |
Last Updated: | January 17, 2013 |
Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) Brazil: Ministry of Health |
Keywords provided by French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS):
HIV Tuberculosis Pharmacokinetics Raltegravir |
France Brazil treatment naive |
Additional relevant MeSH terms:
HIV Infections Acquired Immunodeficiency Syndrome Tuberculosis Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Mycobacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections |
Bacterial Infections Rifampin Lamivudine Efavirenz Antibiotics, Antitubercular Anti-Bacterial Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Antitubercular Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Leprostatic Agents Nucleic Acid Synthesis Inhibitors Reverse Transcriptase Inhibitors |
ClinicalTrials.gov processed this record on March 03, 2013